Two more Big Pharma CEOs enjoyed hefty raises in 2018, leaving the industry’s only major league female chief in firm control of last place
By any measure, Merck had a big year in 2018 as its PD-1 drug cruised into first place for the megablockbuster checkpoint market. And …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
